{"nct_id":"NCT03221634","title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)","status":"WITHDRAWN","status_verified_date":"2019-03","start_date":"2017-08-01","start_date_type":"ESTIMATED","primary_completion_date":"2019-03-20","primary_completion_date_type":"ESTIMATED","completion_date":"2021-06-10","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}